Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension of ONO-2506PO in ALS
2007-004723-37Phase 2Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of arundic acid in amyotrophic lateral sclerosis (ALS), sponsored by Ono Pharmaceutical. Started Jan 2008; status: terminated.
02
Drugs
arundic acid
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2007-004723-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004723-37.